Abstract
Abstract The prevalence rate of prostate cancer is very high and unfortunately causes many deaths worldwide. This study aimed to prepare [113mIn]In-PSMA as a novel agent for single photon emission computed tomography (SPECT) imaging of prostate cancer. 113mIn was eluted from an in-house made 113Sn/113mIn generator in chloride form, and its radionuclide, chemical and radiochemical purities was studied. [113mIn]In-PSMA was prepared with radiochemical purity (RCP) > 99 % under optimal labeling conditions. The biodistribution of the labeled compound was studied in normal rats, showed the major activity in the urine and kidneys as the main excretion route from the body. Considerable uptake was observed in the prostate and salivary glands as the PSMA-expressing organs. These data are in complete agreement with the other published data on PSMA-labeled compounds both in animals and humans. The results demonstrated [113mIn]In-PSMA can be considered as a good option for SPECT imaging of prostate cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
